Education & Training

2005: B.S. in Biomolecular Biotechnologies, University of Bologna, Italy

• Thesis: Chiron Vaccines, Siena, Italy (PI: Vincenzo Scarlato)

2007: M.S. in Biomolecular Biotechnologies, University of Bologna, Italy

• Thesis: Max Planck Institute, Goettingen, Germany (PI: Markus Zweckstetter / Christian Griesinger / Stefano Ciurli)

2011: Ph.D. in Physical Chemistry, ETH Zuerich, Switzerland (Thesis co-advisors: Hans-Uwe Simon / Beat Meier)
2011-2016: Postdoc, UCLA, Los Angeles, US (PI: David Eisenberg)

Honors & Awards

2005: Bachelor Degree, cum Laude honors
2006: UNIBO Fellowship for Research Training in a Foreign Country
2006: IAESTE – DAAD fellowship
2007: Master Degree, cum Laude honors
2010: Chip Miller Memorial Junior Research Travel Award
2014: AACR-Millennium Fellowship in Prostate Cancer Research
2014: UCLA Clinical Translational Science Institute Voucher Award
2014: Elsa U. Pardee Foundation Grant recipient
2015: DGSOM Travel Childcare Award
2015: UCLA Clinical Translational Science Institute Voucher Award
2015: AACR-Marsha Rivkin Center for Ovarian Cancer Research Scholar-In-Training Award
2015: Hirshberg Foundation Seed Award
2016: Worldwide Cancer Research Grant recipient
2016: UCLA Clinical Translational Science Institute Voucher Award 

Selected Talks

2010: XIIth International Symposium on Amyloidosis: From molecular mechanisms toward the cure of systemic amyloidosis

• Toward a Comprehension of Functional Aggregation into Amyloids in Pituitary Secretory Granules

2010: Gordon Research Conference: Proprotein Processing, Trafficking & Secretion

• A Role for Functional Amyloids in the Secretory Pathway

2012: Cold Spring Harbor Laboratory Meeting: Mechanisms and Models of Cancer

• Design and characterization of p53 aggregation inhibitors: A new approach to cancer therapeutics

2014: 13th International Summer School: Inflammation, Immunomodulation, Inspiration

• Inhibiting p53 aggregation restores its function and induces apoptosis

2015: AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities

• A designed inhibitor of p53 self-aggregation rescues p53 tumor-suppression function in high-grade serous ovarian carcinoma